[go: up one dir, main page]

SG11201607109QA - Antibodies that bind egfr and erbb3 - Google Patents

Antibodies that bind egfr and erbb3

Info

Publication number
SG11201607109QA
SG11201607109QA SG11201607109QA SG11201607109QA SG11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA SG 11201607109Q A SG11201607109Q A SG 11201607109QA
Authority
SG
Singapore
Prior art keywords
erbb3
antibodies
bind egfr
egfr
bind
Prior art date
Application number
SG11201607109QA
Inventor
Ton Logtenberg
Mark Throsby
Robertus Cornelis Roovers
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11201607109QA publication Critical patent/SG11201607109QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201607109QA 2014-02-28 2015-02-27 Antibodies that bind egfr and erbb3 SG11201607109QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14157351 2014-02-28
PCT/NL2015/050124 WO2015130172A1 (en) 2014-02-28 2015-02-27 Antibodies that bind egfr and erbb3

Publications (1)

Publication Number Publication Date
SG11201607109QA true SG11201607109QA (en) 2016-09-29

Family

ID=50184826

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607109QA SG11201607109QA (en) 2014-02-28 2015-02-27 Antibodies that bind egfr and erbb3

Country Status (9)

Country Link
US (3) US10844127B2 (en)
EP (2) EP3786186A1 (en)
JP (1) JP6771385B2 (en)
AU (1) AU2015223566B2 (en)
CA (1) CA2941030A1 (en)
ES (1) ES2816624T3 (en)
NZ (1) NZ724013A (en)
SG (1) SG11201607109QA (en)
WO (1) WO2015130172A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
ES2692951T3 (en) 2012-09-27 2018-12-05 Merus N.V. Bispecific IgG antibodies as T cell couplers
KR20160145560A (en) 2014-02-28 2016-12-20 메뤼스 엔.페. Antibody that binds erbb-2 and erbb-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
JP7010811B2 (en) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ Human CD3 binding antibody
KR20180100305A (en) 2015-10-23 2018-09-10 메뤼스 엔.페. Binding molecules that inhibit cancer growth
CN113862300A (en) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 Transgenic rabbits with common light chain
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
CA3054381A1 (en) * 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
JP2020530028A (en) * 2017-08-09 2020-10-15 メルス ナムローゼ フェンノートシャップ Antibodies that bind to EGFR and cMET
KR20200139189A (en) 2018-03-30 2020-12-11 메뤼스 엔.페. Polyvalent antibody
CN113439089A (en) 2018-12-31 2021-09-24 美勒斯公司 truncated multivalent multivariate
EP3924384A1 (en) 2019-02-14 2021-12-22 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3
PH12021552833A1 (en) 2019-05-09 2023-01-16 Merus Nv Variant domains for multimerizing proteins and separation thereof
MX2022002096A (en) 2019-08-19 2022-03-17 Merus Nv Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor.
CN114761436A (en) * 2019-10-24 2022-07-15 美勒斯公司 Means and methods for treating subjects with HER2 and HER3 positive cancers
JP2023523006A (en) 2020-04-24 2023-06-01 メルス ナムローゼ フェンノートシャップ Cancer treatment with antibodies that bind to LGR5 and EGFR
MX2023003304A (en) * 2020-09-21 2023-05-09 Systimmune Inc Egfr binding complex and method of making and using thereof.
MX2023006983A (en) 2020-12-15 2023-06-26 Merus Nv Treatment of cancers with an antibody that binds lgr5 and egfr.
CN118055949A (en) 2021-10-06 2024-05-17 美勒斯公司 Treatment of cancers with high EGFR expression treated with antibodies that bind at least EGFR
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
CN120058955A (en) 2022-03-07 2025-05-30 美勒斯公司 Treatment with antibodies that bind EGFR and cMET
AU2023408531A1 (en) 2022-12-23 2025-07-17 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
WO2024144401A1 (en) 2022-12-28 2024-07-04 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
KR100255717B1 (en) 1991-07-15 2000-05-01 그레이엄 브레레톤 Production method of antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2246069T3 (en) 1997-05-02 2006-02-01 Genentech, Inc. PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
DK1161548T4 (en) 1999-04-15 2010-03-01 Crucell Holland Bv Recombinant protein production in a human cell using sequences encoding adenovirus E1 protein
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ATE466941T1 (en) 2001-07-04 2010-05-15 Chromagenics Bv DNS SEQUENCES WITH ANTI-REPRESSOR ACTIVITY
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (en) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 Interaction predicting device
ES2368733T3 (en) 2002-07-18 2011-11-21 Merus B.V. RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES.
JP4589914B2 (en) 2003-01-07 2010-12-01 シムフォゲン・アクティーゼルスカブ Method for producing recombinant polyclonal protein
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
KR101201464B1 (en) 2004-05-05 2012-11-14 메리맥 파마슈티컬즈, 인크. Bispecific binding agents for modulating biological activity
MXPA06014075A (en) 2004-06-03 2007-03-15 Novimmune Sa Anti-cd3 antibodies and methods of use thereof.
JP2008511337A (en) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド Heteromultimeric molecule
JP4852046B2 (en) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー Binding molecules for the treatment and detection of cancer
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF
CA2678181C (en) 2007-02-16 2016-12-13 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
KR101626988B1 (en) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
AU2008270972B2 (en) 2007-07-02 2013-10-24 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc ANTI-CLL-1 ANTIBODIES
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US9404928B2 (en) 2008-02-05 2016-08-02 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
SI2147594T1 (en) 2008-06-27 2014-02-28 Merus B.V. Antibody producing non-human mammals
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
BRPI0921586A2 (en) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc human serum albumin articulators and conjugates thereof
KR20110120891A (en) 2009-01-15 2011-11-04 래버러토리 코포레이션 오브 아메리카 홀딩스 Method of determination of patient response by measurement of HER-3
WO2010084197A1 (en) 2009-01-26 2010-07-29 Genmab A/S Methods for producing mixtures of antibodies
TWI461211B (en) * 2009-03-20 2014-11-21 Genentech Inc Anti-her antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX342623B (en) 2009-06-26 2016-10-06 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
BR112012003809A2 (en) 2009-08-21 2019-09-24 Merrimack Pharmaceuticals Inc isolated monoclonal antibody or antigen binding portion thereof, composition and method for treating cancer in an individual.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5960598B2 (en) 2009-11-04 2016-08-02 アフィボディ・アーベー HER3 binding polypeptide
RU2724663C2 (en) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Mouse with common light chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
WO2012022814A1 (en) 2010-08-20 2012-02-23 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
MX2013009732A (en) 2011-02-24 2013-12-06 Merrimack Pharmaceuticals Inc Combination therapies comprising anti-erbb3 agents.
EP2683741A2 (en) 2011-03-11 2014-01-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
CA2828043A1 (en) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
KR20200052383A (en) 2011-03-25 2020-05-14 아이크노스 사이언스 에스. 아. Hetero-dimeric Immunoglobulins
NO2707391T3 (en) 2011-05-13 2018-04-07
EP2722343A4 (en) 2011-06-20 2014-12-17 Kyowa Hakko Kirin Co Ltd ANTI-erbB3 ANTIBODY
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN103917562B (en) 2011-09-30 2016-07-06 瑞泽恩制药公司 Anti-ErbB3 antibody and application thereof
CN104093743B (en) 2011-11-23 2018-04-24 医学免疫有限责任公司 It is specific to binding molecule of HER3 and application thereof
SG11201402784WA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
ES2758433T3 (en) 2011-12-05 2020-05-05 Novartis Ag Antibodies to epidermal growth factor receptor 3 (HER3)
CN102448183A (en) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 Uu interface reconfiguration method and equipment
WO2013134686A1 (en) 2012-03-09 2013-09-12 Promega Corporation pH SENSORS
SG11201406079TA (en) * 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
PL2838917T3 (en) 2012-04-20 2019-12-31 Merus N.V. Methods and means for the production of heterodimeric Ig-like molecules
TW201843172A (en) 2012-06-25 2018-12-16 美商再生元醫藥公司 anti-EGFR antibody and use thereof
ES2692951T3 (en) 2012-09-27 2018-12-05 Merus N.V. Bispecific IgG antibodies as T cell couplers
JP2015532306A (en) 2012-10-15 2015-11-09 チューリッヒ大学 Bispecific HER2 ligand for cancer therapy
ES2700231T3 (en) 2012-11-21 2019-02-14 Janssen Biotech Inc Bispecific EGFR / c-Met antibodies
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
CA2900955A1 (en) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
CA2908515A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
KR20160145560A (en) 2014-02-28 2016-12-20 메뤼스 엔.페. Antibody that binds erbb-2 and erbb-3
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
MA41123A (en) 2014-12-02 2017-10-10 Oncomed Pharm Inc POLYTHERAPY FOR CANCER TREATMENT
JP7010811B2 (en) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ Human CD3 binding antibody
KR20180100305A (en) 2015-10-23 2018-09-10 메뤼스 엔.페. Binding molecules that inhibit cancer growth
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
CN110997000A (en) 2017-03-31 2020-04-10 美勒斯公司 Antibodies for treatment of ErbB-2/ErbB-3 positive tumors

Also Published As

Publication number Publication date
EP3110846A1 (en) 2017-01-04
ES2816624T3 (en) 2021-04-05
EP3110846B1 (en) 2020-08-19
US11820825B2 (en) 2023-11-21
US20210155698A1 (en) 2021-05-27
CA2941030A1 (en) 2015-09-03
JP2017512756A (en) 2017-05-25
AU2015223566B2 (en) 2020-10-08
NZ724013A (en) 2019-11-29
US20170058035A1 (en) 2017-03-02
EP3786186A1 (en) 2021-03-03
US20240052043A1 (en) 2024-02-15
US10844127B2 (en) 2020-11-24
AU2015223566A1 (en) 2016-09-01
WO2015130172A1 (en) 2015-09-03
JP6771385B2 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
SG11201607109QA (en) Antibodies that bind egfr and erbb3
ZA202105920B (en) Antibody that binds erbb-2 and erbb-3
IL252804A0 (en) Anti-c10orf54 antibodies and uses thereof
IL251248A0 (en) Anti-interleukin-33 antibodies and uses thereof
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
IL252929B (en) Humanized anti-acth antibodies and use thereof
IL247315A0 (en) Anti-acth antibodies and use thereof
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
IL247590A0 (en) Bi-specific antibodies and uses thereof
PL3233912T3 (en) Antibodies that bind human c6 and uses thereof
PT3805268T (en) Antibody that binds erbb-2 and erbb-3